What happened with XAIR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Beyond Air’s LungFit PH delivers nitric oxide to treat newborns with persistently high blood pressure in the lungs, a condition called persistent pulmonary hypertension of the newborn. It is the company’s only approved product. Hospitals pay a fixed rental fee under contracts that also cover consumables and device-related services. These leases provide most of the company’s revenue.
The business depends on hospitals adopting LungFit PH and on government and private insurers covering treatment adequately. Beyond Air outsources manufacturing to Spartronics and Medisize, each operating at a single facility; replacement sources require FDA approval. The company may promote LungFit PH only for FDA-approved uses, even though physicians may independently use it for other conditions.
Beyond Air is also developing other treatments, including cancer therapies through Beyond Cancer and neurological therapies through NeuroNos. Those subsidiaries do not yet generate revenue, and other candidates need further development and regulatory authorization before commercialization. The company still needs additional funding to support its operations before it can become profitable.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond Air’s results hinge on hospitals choosing LungFit PH over established nitric-oxide treatments, including Mallinckrodt’s INOMAX and VERO Biotech’s GENOSYL, neither represented in this list.
Linde competes for hospitals’ nitric-oxide treatment spending with Beyond Air, which rents out LungFit PH: Linde markets generic inhaled nitric oxide using NOxBOX and holds European INOMAX rights. Watch those offerings rather than Linde’s overall sales, since this market is only a small part of its gas business serving healthcare and many other industries.
Fed Interest Rate Decision
Beyond Air needs more funding and carries a $13.5 million loan at 15% interest, so the Fed’s policy rate—the rate that guides borrowing costs across the economy—can affect what it pays to borrow and how costly it is to raise capital.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates higher than expected, new borrowing may cost Beyond Air more and make needed financing harder to secure, adding pressure while it funds operations and commercialization.
If it comes in below expectations
If the Fed sets rates lower than expected, new borrowing may become cheaper and financing easier for Beyond Air to obtain, easing pressure as it seeks funds for operations and commercialization.
Linde plc earningsLIN
Linde sells generic inhaled nitric oxide through NOxBOX and holds European INOMAX rights; its report can show whether hospital demand for nitric-oxide treatment supports Beyond Air's LungFit PH rental business.
Look for information on Linde's NOxBOX and European INOMAX business, not its overall sales across healthcare and other industries. Evidence of steady or stronger demand would show hospitals still use nitric-oxide treatment, a market Beyond Air can pursue for LungFit PH rentals; weaker demand would mean a less supportive environment for Beyond Air to win hospital adoption and grow rentals.
Beyond Air, Inc. earningsThis company
Beyond Air leases LungFit PH devices to hospitals, and this report will show whether lease revenue is growing faster than device depreciation and other costs to support its commercial business.
Read LungFit PH lease revenue alongside related costs, especially device depreciation included in cost of revenues. Revenue growth without a similar rise in costs would show the hospital-lease business is expanding and improving its economics; flat revenue or faster-rising costs would show the devices are not yet generating enough return. With the company still loss-making and needing outside funding, these figures indicate whether commercialization is beginning to ease that financing burden.
